Validación del cuestionario FoP-Q-SF (Fear of Progression Questionnaire- Short Form) para su utilización en la evaluación del temor a la progresión de la enfermedad en pacientes colombianos con enfermedad renal crónica

dc.contributor.advisorSanchez Pedraza, Ricardospa
dc.contributor.advisorSanabria, Rafael Mauriciospa
dc.contributor.authorPatiño Maza, Giancarlosspa
dc.date.accessioned2025-11-05T01:48:16Z
dc.date.available2025-11-05T01:48:16Z
dc.date.issued2025
dc.descriptionilustraciones, diagramasspa
dc.description.abstractIntroducción: el temor a la progresión de la enfermedad es un constructo que se ha venido estudiando desde los años 80 en pacientes con cáncer, sin embargo, en los últimos años se ha identificado la existencia del mismo en pacientes con enfermedades crónicas. Este tipo de temores se correlaciona con la calidad de vida y con la presencia de síntomas ansiosos o depresivos, pudiendo así ser determinantes en los desenlaces de estos pacientes. Objetivo: validar la escala FoP-Q- SF (Fear of Progression Questionnaire Short Form) para su uso en la evaluación del temor a la progresión de la enfermedad en pacientes con enfermedad renal crónica en Colombia. Métodos: se realizó la validación mediante los métodos de teoría clásica y teoría de respuesta al ítem utilizando un modelo Rasch. Se realizó una adaptación transcultural inicialmente y luego se evaluó la confiabilidad del instrumento, la validez convergente y divergente. También se llevó a cabo un análisis factorial exploratorio y luego un análisis factorial confirmatorio. En la validación mediante el modelo Rasch se verificaron los supuestos de unidimensionalidad y de independencia local, además, se evaluó la confiabilidad y el ajuste de personas y de ítems. Resultados: el instrumento FoP-Q- SF (Fear of Progression Questionnaire Short Form) se aplicó a 446 pacientes con enfermedad renal crónica, principalmente en estadio 3, que asisten a una clínica de atención ambulatoria de Baxter ® en la ciudad de Bogotá (Colombia). La escala mostró una adecuada consistencia interna (Alfa de Cronbach = 0.83, Omega de McDonald = 0.83 y GLB = 0.88. La confiabilidad tes-retest fue muy buena mostrando un coeficiente de concordancia de Lin de 0.97. El análisis factorial exploratorio de la escala con 12 ítems mostró que la estructura de tres factores era la mejor solución, pero dos ítems se agrupaban en un único factor y el ítem 4 tenía una varianza negativa, lo cual se considera un problema de especificación del modelo; ante esto, se decidió eliminar el ítem 4 del instrumento. En el análisis factorial confirmatorio se comparó el modelo unifactorial con el de dos factores y se encontró que este último tenía un mejor ajuste. La escala cumple el supuesto de unidimensionalidad y de independencia local siempre y cuando se eliminé el ítem 4. El índice de confiabilidad de las personas fue de 0.75 y el de separación fue de 1.75 los que permite decir que la confiabilidad es aceptable. Existe sobreposición de algunos ítems, pero el parafraseo de los ítems indica que miden diferentes aspectos del rasgo. Conclusión: la escala sin el ítem número 4 tiene una adecuada confiabilidad y validez para poder realizar una medición adecuada del temor a la progresión de la enfermedad en pacientes con enfermedad renal crónica. (Texto tomado de la fuente).spa
dc.description.abstractIntroduction: Fear of disease progression is a construct that has been studied since the 1980s in cancer patients; however, in recent years, its presence has also been identified in patients with chronic diseases. Such fears are correlated with quality of life and the presence of anxiety or depressive symptoms, and may therefore be determinants of patient outcomes. Objective: To validate the FoP-Q-SF (Fear of Progression Questionnaire–Short Form) for use in assessing fear of disease progression in patients with chronic kidney disease in Colombia. Methods: Validation was carried out using both classical test theory and item response theory with a Rasch model. A cross-cultural adaptation was performed first, followed by assessments of the instrument’s reliability, and convergent and divergent validity. An exploratory factor analysis was conducted, followed by a confirmatory factor analysis. In the Rasch model validation, the assumptions of unidimensionality and local independence were verified, and the reliability and fit of persons and items were evaluated. Results: The FoP-Q-SF was administered to 446 patients with chronic kidney disease, mainly stage 3, who attended a Baxter® outpatient clinic in Bogotá, Colombia. The scale showed adequate internal consistency (Cronbach’s alpha = 0.83, McDonald’s omega = 0.83, and GLB = 0.88). Test–retest reliability was very good, with a Lin’s concordance coefficient of 0.97. The exploratory factor analysis of the 12-item scale indicated that a three-factor structure provided the best solution; however, two items clustered into a single factor and item 4 showed negative variance, indicating a model specification issue. Consequently, item 4 was removed from the instrument. In the confirmatory factor analysis, the one-factor model was compared with a two-factor model, and the latter showed a better fit. The scale met the assumptions of unidimensionality and local independence once item 4 was removed. The person reliability index was 0.75 and the separation index was 1.75, indicating acceptable reliability. Although some item overlap was observed, paraphrasing analysis indicated that they measure different aspects of the construct. Conclusion: The scale, without item 4, demonstrates adequate reliability and validity for appropriately measuring fear of disease progression in patients with chronic kidney disease.eng
dc.description.degreelevelMaestría
dc.description.degreenameMagíster en Epidemiología Clinica
dc.description.sponsorshipBaxter RTSspa
dc.format.extent110 páginasspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/89103
dc.language.isospa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Maestría en Epidemiología Clínicaspa
dc.relation.indexedBiremespa
dc.relation.references1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global , regional , and national incidence , prevalence , and years lived with disability for 354 diseases and injuries for 195 countries and territories , 1990 – 2017 : a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(November):1990–2017.
dc.relation.references2. Scott, KM; Von Korf M. Age patterns in the prevalence of DSM-IV depressive/anxiety disorders with and without physical co-morbidity de. Psychol Med. 2008;38(11):1659–69
dc.relation.references3. Tamayo N, Gómez-restrepo C, Ramírez S. Prevalencia de trastornos del afecto y de ansiedad en personas con condiciones crónicas . Resultado 2015. Rev Colomb Psiquiatr [Internet]. 2016;(x x):1–6. Available from: http://dx.doi.org/10.1016/j.rcp.2016.06.001
dc.relation.references4. Riba MB, Donovan KA, Andersen B, Braun I, Breitbart WS, Brewer BW, et al. Distress Management, Version 3.2019. J Natl Compr Canc Netw. 2019;17(10):1229– 49.
dc.relation.references5. Herschbach P, Dinkel A. Fear of Progression. Psychooncology. 2014;11–29.
dc.relation.references6. Herschbach P, Berg P, Dankert A, Duran G, Engst-hastreiter U, Waadt S, et al. Fear of progression in chronic diseases Psychometric properties of the Fear of Progression Questionnaire. 2005;58:505–11
dc.relation.references7. Hinz A, Mehnert A, Ernst J. Fear of progression in patients 6 months after cancer rehabilitation — a validation study of the fear of progression questionnaire FoP-Q-12. 2014;
dc.relation.references8. Von Anja Mehnert, Peter Herschbach PB, Gerhard Henrich UK. Progredienzangst bei Brustkrebspatientinnen – Validierung der Kurzform des. Z Psychosom Med Psychother. 2006;52:274–88
dc.relation.references9. Nakata H, Halbach S, Geiser F, Stock S, Kowalski C, Enders A, et al. Health literacy, mental disorders and fear of progression and their association with a need for psycho- oncological care over the course of a breast cancer treatment. Psychol Health Med. 2020;
dc.relation.references10. Herschbach, P., Dankert, A., Duran-Atzinger, G., Waadt S, Engst-Hastreiter, U., Keller, M. & Henrich G. Diagnostik von Progredienzangst –Entwicklung eines Fragebogens zur Erfassung von Progredienzangst bei Patienten mit Krebserkrankungen, Diabetes mellitus und entzündlich-rheumatischen Erkrankungen in der Rehabilitation. TU-München; 2001.
dc.relation.references11. Herschbach P, Waadt S, Engst-hastreiter U, Henrich G, Dinkel A. Group Psychotherapy of Dysfunctional Fear of Progression in Patients with Chronic Arthritis or Cancer. 2010;31–8
dc.relation.references12. Kwakkenbos L, Lankveld WGJM Van, Vonk MC, Becker ES, Hoogen FHJ Van Den, Ende CHM Van Den. Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis , including fear of progression and appearance self-esteem. J Psychosom Res [Internet]. 2012;72(3):199–204. Available from: http://dx.doi.org/10.1016/j.jpsychores.2011.12.005
dc.relation.references13. Nielsen J, Saliger J. Facing the Unknown: Fear of Progression Could Be a Relevant Psychological Risk Factor for Depressive Mood States among Patients with Multiple Sclerosis. Psychother Psychosom. 2018;1–3.
dc.relation.references14. Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer- related intrusive cognitions in breast cancer survivors. Psychooncology. 2009;1280(March):1273–80
dc.relation.references15. Sarkar S, Scerwarth A. Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(January):1217–22.
dc.relation.references16. Pfaff, H., Ernstmann, N., Groß, S. E., Ansmann, L., Gloede, T. D., Nitzsche, A., Baumann W, Wirtz, M., & Neumann M. Fragebogen für Patienten mit Kolorektalkarzinom in ambulanter onkologischer Versorgung (WIN ON Pat) Kennzahlenhandbuch. Cologne; 2014
dc.relation.references17. Hill NR, Fatoba ST, Oke JL, Hirst JA, Callaghan AO, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE 11 [Internet]. 2016;7:1–18. Available from: http://dx.doi.org/10.1371/journal.pone.0158765
dc.relation.references18. Palmer SC, Vecchio M. Association Between Depression and Death in People With CKD : A Meta-analysis of Cohort Studies. Am J Kidney Dis [Internet]. 2013;62(3):493–505. Available from: http://dx.doi.org/10.1053/j.ajkd.2013.02.369
dc.relation.references19. Loosman WL, Rottier MA, Honig A, Siegert CEH. Association of depressive and anxiety symptoms with adverse events in Dutch chronic kidney disease patients : a prospective cohort study. BMC Nephrol [Internet]. 2015;1–8. Available from: http://dx.doi.org/10.1186/s12882-015-0149-7
dc.relation.references20. NORTHOUSE L. Mastectomy patients and the fear of cancer recurrence. Cancer Nurs. 1981;4(3):213–20
dc.relation.references21. Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, et al. From normal response to clinical problem : definition and clinical features of fear of cancer recurrence. Support Care Cancer [Internet]. 2016;3–6. Available from: http://dx.doi.org/10.1007/s00520-016-3272-5
dc.relation.references22. Simard S, Savard J, Ivers H. Fear of cancer recurrence : specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010;4:361–71
dc.relation.references23. Simard S, Thewes B, Humphris G. Fear of cancer recurrence in adult cancer survivors : a systematic review of quantitative studies. J Cancer Surviv. 2013;300–22
dc.relation.references24. Prins J, Kwakkenbos L, Hoogen Fhjvanden, Ende Chmvanden. Validity of the Fear of Progression Questionnaire- Short Form in Patients With Systemic Sclerosis. 2012;64(6):930–4
dc.relation.references25. Luz, Johanne; Martini, Julia; Clever K. Psychometric Properties of the Fear of Progression Questionnaire for Children ( FoP-Q-SF / C ). Klin Padiatr. 2020;232:136– 42.
dc.relation.references26. Fidika A, Herle M, Herschbach P, Goldbeck L. Fear of disease progression questionnaire for parents : Psychometric properties based on a sample of caregivers of children and adolescents with cystic fi brosis. J Psychosom Res [Internet]. 2015;79(1):49–54. Available from: http://dx.doi.org/10.1016/j.jpsychores.2015.02.014
dc.relation.references27. Clever K, Schepper F, Pletschko T, Herschbach P, Christiansen H, Martini J. Psychometric properties of the Fear of Progression Questionnaire for parents of children with cancer ( FoP-Q-SF / PR ). 2018;107(October 2017):7–13
dc.relation.references28. Berg P, Book K, Dinkel A, Henrich G, Marten-mittag B, Mertens D. Progredienzangst bei chronischen Erkrankungen. Psychother Psych Med. 2011;61:32–7
dc.relation.references29. Zimmermann T, Alsleben M, Heinrichs N. Progredienzangst gesunder Lebenspartner von chronisch erkrankten Patienten. Psychother Psych Med. 2012;62:344–51
dc.relation.references30. Stenzel N, Rief W, Pinzer S, Kenn K. Progredienzangst und End-of-Life-Ängste bei COPD-Patienten Zusammenhänge mit allgemeiner psychischer Symptomatik und Lebensqualität. 2012;111–8
dc.relation.references31. Waldenburger N, Steinecke M, Peters L, Jünemann F, Bara C. Depression , anxiety , fear of progression , and emotional arousal in couples after left ventricular assist device implantation. 2020;(July):3022–8
dc.relation.references32. Herschbach P, Book K, Dinkel A, Berg P, Waadt S, Duran G. Evaluation of two group therapies to reduce fear of progression in cancer patients. 2010;471–9
dc.relation.references33. Sabariego C, Brach M, Herschbach P, Berg P, Stucki G. Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients. Eur J Heal Econ. 2011;12:489–97
dc.relation.references34. Savard J, Ivers H. The evolution of fear of cancer recurrence during the cancer care trajectory and its relationship with cancer characteristics. J Psychosom Res [Internet]. 2013;74(4):354–60. Available from: http://dx.doi.org/10.1016/j.jpsychores.2012.12.013
dc.relation.references35. Mehnert A, Koch UWE, Sundermann C, Dinkel A. Predictors of fear of recurrence in patients one year after cancer rehabilitation : A prospective study. Acta Oncol (Madr). 2013;(August 2012):1102–9
dc.relation.references36. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological Side Effects of Breast Cancer Screening. Heal Psychol. 1991;10(4):259–67
dc.relation.references37. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the Process of Cross-Cultural Adaptation of Self-Report Measures. Spine (Phila Pa 1976). 2000;25(24):3186–91
dc.relation.references38. Kuli D, Bottomley A, Velikova G, Greimel E. EORTC quality of life group 2017. Translation procedure. European Organization for Research and Treatment of Cancer; 2017. p. 1–26
dc.relation.references39. Sanchez R, Echeverry J. Validación de Escalas de Medición en Salud. Rev Salud pública. 2004;6(3):302–18
dc.relation.references40. Mcneish D. Thanks Coefficient Alpha , We ’ ll Take It From Here. Psychol Methods. 2017
dc.relation.references41. Nunnally JC, Bernstein IH. Psychometric theory. Third. Vol. 1. McGraw-Hill, inc; 1994. 264–265 p.
dc.relation.references42. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med [Internet]. 2016;15(2):155–63. Available from: http://dx.doi.org/10.1016/j.jcm.2016.02.012
dc.relation.references43. Portney LG, Company FAD. Foundations of Clinical Research: Applications to Evidence-Based Practice. Fourth. F. A. Davis Company; 2020. 491 p
dc.relation.references44. Mahendran R, Liu J, Kuparasundram S, Griva K. Validation of the English and simplified Mandarin versions of the Fear of Progression Questionnaire – Short Form in Chinese cancer survivors. 2020;4–10
dc.relation.references45. Goebel S, Mehdorn HM. Fear of disease progression in adult ambulatory patients with brain cancer : prevalence and clinical correlates. Support Care Cancer. 2019
dc.relation.references46. Esser P, Götze H, Mehnert-theuerkauf A, Knoop H, Kuba K. Fear of progression and its role in the relationship of cancer-related fatigue with physical functioning and global quality of life – A register-based study among hematological cancer survivors. J Psychosom Res J. 2019;127(September):109844
dc.relation.references47. Yang Y, Sun H, Liu T, Zhang J, Wang H, Liang W, et al. Factors associated with fear of progression in chinese cancer patients : sociodemographic , clinical and psychological variables. J Psychosom Res [Internet]. 2018;114(June):18–24. Available from: https://doi.org/10.1016/j.jpsychores.2018.09.003
dc.relation.references48. Parker PA, Davis JW. The Relationship Between Illness Uncertainty, Anxiety, Fear of Progression, and Quality of Life in Men With Favorable Risk Prostate Cancer Undergoing Active Surveillance Patricia. BJU Int. 2016;117(3):469–77
dc.relation.references49. Lebel S, Mutsaers B, Tomei C, Se C, Jones G, Petricone-westwood D, et al. Health anxiety and illness-related fears across diverse chronic illnesses : A systematic review on conceptualization , measurement ,. 2020. 1–48 p
dc.relation.references50. Rico J, Restrepo M, Molina M. Adaptación y validación de la escala hospitalaria de ansiedad y depresión (had) en una muestra de pacientes con cáncer del instituto nacional de cancerologia de colombia. Av en Medición. 2005;3:73–86
dc.relation.references51. Aggarwal HK, Jain D, Dabas G, Yadav RK. Prevalence of depression , anxiety and insomnia in chronic kidney disease patients and their co-relation with the demographic variables. Prilozi. 2017
dc.relation.references52. Peipert JD, Bentler PM, Klicko K, Hays RD. Psychometric Properties of the Kidney Disease Quality of Life 36-Item Short-Form Survey (KDQOL-36) in the United States. Am J Kidney Dis [Internet]. 2018;71(4):461–8. Available from: https://doi.org/10.1053/j.ajkd.2017.07.020
dc.relation.references53. Fabrigar LR, Wegener DT, Maccallum RC, Strahan EJ. Evaluating the Use of Exploratory Factor Analysis in Psychological Research. Psychol Methods. 1999;4(3):272–99
dc.relation.references54. Costello AB, Osborne JW. Best Practices in Exploratory Factor Analysis : Four Recommendations for Getting the Most From Your Analysis. Pract Assessment, Res Eval. 2005;10(7)
dc.relation.references55. Tabachnick BG, Fidell LS. Using Multivariate Statistics. Seventh. 2019
dc.relation.references56. Maccallum RC, Browne MW, Sugawara HM. Power Analysis and Determination of Sample Size for Covariance Structure Modeling. Psychol Methods. 1996;I(2):130–49
dc.relation.references57. Mora-esquivel R, Halabí TV. Tamaño de la muestra en modelos de ecuaciones estructurales con constructos latentes : Un método práctico. Rev Electrónica “Actualidades Investig en Educ [Internet]. 2017;17(1):1–34. Available from: http://dx.doi.org/10.15517/aie.v17i1.27294%0A
dc.relation.references58. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness : a critical review and recommendations. J Clin Epidemiol. 2000;53:459–68
dc.relation.references59. Liang M, Lew R, Stucki G, Fortin P, Daltroy L. Measuring Clinically Important Changes With Patient-Oriented Questionnaires. Med Care. 2002;40(4-Supplement II):45–51
dc.relation.references60. Hurley AMYE, Scandura TA, Chester A, Brannick MT, Seers A, Vandenberg RJ, et al. Exploratory and confirrmatory factor analysis : guidelines , issues , and alternatives. J Organ Behav. 1997;18(February):667–83
dc.relation.references61. Izquierdo I, Olea J, Abad FJ. Exploratory factor analysis in validation studies : Uses and recommendations. Psicothema. 2014;26(3):395–400
dc.relation.references62. Anthoine E, Moret L, Regnault A, S V. Sample size used to validate a scale : a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:1–10
dc.relation.references63. Sapnas KG, Zeller RA. Minimizing Sample Size When Using Exploratory Factor Analysis for Measurement. J Nurs Meas. 2002;10(2):135–54
dc.relation.references64. Preacher KJ, Coffman DL. Computing power and minimum sample size for RMSEA [Internet]. http://quantpsy.org/.; 2006. Available from: http://www.quantpsy.org/rmsea/rmsea.htm
dc.relation.references65. Bonett DG. Sample Size Requirements for Testing and Estimating Coefficient Alpha. J Educ Behav Stat. 2002;27(4):335–40.
dc.relation.references66. Bonett DG. Sample size requirements for estimating intraclass correlations with desired precision. Stat Med. 2002;21:1331–1335.
dc.relation.references67. War Non Arifin. Sample Size Calculator (web) [Internet]. 2021. Available from: http://wnarifin.github.io
dc.relation.references68. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Off J Int Soc Nephrol. 2013;3(1).
dc.relation.references69. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Second Edi. Lawrence Erlbaum Associates; 1988. 24–27 p
dc.relation.references70. Boone WJ, Staver JR, Yale MS. Rasch Analysis in the Human Sciences. Dordrecht, Países Bajos: Springer; 2014
dc.relation.references71. Rating scale instrument quality criteria [Internet]. Rasch.org. [citado 17 de julio de 2024]. Disponible en: https://www.rasch.org/rmt/rmt211m.htm
dc.relation.references72. Linacre JM. Rasch model estimation: further topics. J Appl Meas. 2004;5(1):95–110
dc.relation.references73. Debelak R, Koller I. Testing the local independence assumption of the Rasch model with Q 3-based nonparametric model tests. Appl Psychol Meas [Internet]. 2020;44(2):103–17. Disponible en: http://dx.doi.org/10.1177/0146621619835501
dc.relation.references74. Linacre JM. Winsteps® Rasch measurement computer program user´s guide. 2024
dc.relation.references75. Reliability, separation, strata statistics [Internet]. Rasch.org. [citado 17 de julio de 2024]. Disponible en: https://www.rasch.org/rmt/rmt63i.htm
dc.relation.references76. Guidelines for rating scales and Andrich thresholds [Internet]. Rasch.org. [citado 17 de julio de 2024]. Disponible en: https://www.rasch.org/rn2.htm
dc.relation.references77. Rico-Fontalvo J, Yama-Mosquera E, Robayo-García A, Aroca-Martínez G, Arango- Álvarez JJ, Barros-Camargo L, et al. Situación de la enfermedad renal crónica en Colombia. Nefrol Latinoam [Internet]. 2022;19(2). Disponible en: http://dx.doi.org/10.24875/nefro.22000030
dc.relation.references78. Kwakkenbos L. Validity of the Fear of Progression Questionnaire- Short Form in Patients With Systemic Sclerosis. Arthritis Care & Research. 2012;64(6):930–4
dc.relation.references79. Sharif-Nia H, Sobhanian P, Froelicher ES, Farhadi B, Hejazi S, Goudarzian AH, et al. A validity and reliability evaluation of fear of progression questionnaire in Iranian breast cancer patients: A methodological study. Health Sci Rep [Internet]. 2024;7(7):e2260. Disponible en: http://dx.doi.org/10.1002/hsr2.2260
dc.relation.references80. Kuang X, Long F, Chen H, Huang Y, He L, Chen L, et al. Correlation research between fear of disease progression and quality of life in patients with lung cancer. Ann Palliat Med [Internet]. 2022;11(1):35–44. Disponible en: http://dx.doi.org/10.21037/apm-21- 2821
dc.relation.references81. Cary, NC: SAS Institute Inc. SAS/STAT® 15.2 User’s Guide [Internet]. 2020. Disponible en: https://documentation.sas.com/doc/en/statug/15.2/statug_factor_details10.htm
dc.relation.references82. Rauschenbach C, Krumm S, Thielgen M, Hertel G. Age and work-related stress: a review and meta-analysis. J Manag Psychol [Internet]. 2013;28(7/8):781–804. Disponible en: http://dx.doi.org/10.1108/jmp-07-2013-0251
dc.relation.references83. Ryu S, Fan L. The relationship between financial worries and psychological distress among U.s. adults. J Fam Econ Issues [Internet]. 2023;44(1):16–33. Disponible en: http://dx.doi.org/10.1007/s10834-022-09820-9
dc.relation.references84. Zacher H, Jimmieson NL, Bordia P. Time pressure and coworker support mediate the curvilinear relationship between age and occupational well-being. J Occup Health Psychol [Internet]. 2014;19(4):462–75. Disponible en: http://dx.doi.org/10.1037/a0036995
dc.relation.references85. Warr P, Butcher V, Robertson I, Callinan M. Older people’s well-being as a function of employment, retirement, environmental characteristics and role preference. Br J Psychol [Internet]. 2004;95(Pt 3):297–324. Disponible en: http://dx.doi.org/10.1348/0007126041528095
dc.relation.references86. Knekta E, Runyon C, Eddy S. One size doesn’t fit all: Using factor analysis to gather validity evidence when using surveys in your research. CBE Life Sci Educ [Internet]. 2019;18(1):rm1. Disponible en: http://dx.doi.org/10.1187/cbe.18-04-0064
dc.relation.references87. Coutts-Bain D, Sharpe L, Pradhan P, Russell H, Heathcote LC, Costa D. Are fear of cancer recurrence and fear of progression equivalent constructs? Psychooncology [Internet]. 2022;31(8):1381-9. Disponible en: http://dx.doi.org/10.1002/pon.5944
dc.relation.references88. Valderrama-Rios MC, Sánchez R, Sanabria M. Psychometric properties of the Kidney Disease Quality of Life short form 36 (KDQOL-36) scale for the assessment of quality of life in Colombian patients with chronic kidney disease on dialysis. Int Urol Nephrol [Internet]. 2024;56(7):2337-50. Disponible en: http://dx.doi.org/10.1007/s11255-024- 03940-x
dc.relation.references89. Kline RB. Principles and practice of structural equation modeling, fourth edition. 4.a ed. Nueva York, NY, Estados Unidos de América: Guilford Publications; 2016
dc.relation.references90. Hu L-T, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling [Internet]. 1999;6(1):1-55. Disponible en: http://dx.doi.org/10.1080/10705519909540118
dc.relation.references91. Bentler PM. Comparative fit indexes in structural models. Psychol Bull [Internet]. 1990;107(2):238-46. Disponible en: http://dx.doi.org/10.1037/0033-2909.107.2.238
dc.relation.references92. Lin L, Hedayat A. Statistical tools for measuring agreement. Nueva York, NY, Estados Unidos de América: Springer; 2012
dc.relation.references93. Steiner MD, Grieder S. EFAtools: An R package with fast and flexible implementations of exploratory factor analysis tools. Journal of Open Source Software. 2020;5(53):2521.
dc.relation.references94. Silva S, Bártolo A, Santos IM, Paiva D, Monteiro S. Validation of the Portuguese version of the Fear of Progression Questionnaire-Short Form (FoP-Q-SF) in Portuguese cancer survivors. Healthcare (Basel) [Internet]. 2022;10(12):2466. Disponible en: http://dx.doi.org/10.3390/healthcare10122466
dc.relation.references95. Hasannezhad Reskati M, Elyasi F, Hosseini SH, Shafizad M, Hedayatizadeh-Omran A, Alizadeh-Navaei R, et al. The psychometric properties of the fear of Progression Questionnaire (FoP-Q) for cancer patients in Iran. J Gastrointest Cancer [Internet]. 2023;54(3):855-66. Disponible en: http://dx.doi.org/10.1007/s12029-022-00875-3
dc.relation.references96. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait- multimethod matrix. Psychol Bull [Internet]. 1959;56(2):81-105. Disponible en: http://dx.doi.org/10.1037/h0046016
dc.relation.references97. Rönkkö M, Cho E. An updated guideline for assessing discriminant validity. Organ Res Methods. 2022;25(1):6-14. Disponible en: http://dx.doi.org/10.1177/1094428120968614
dc.relation.references98. Marsh, H. W., Hau, K. T., Balla, J. R., & Grayson, D. (1998). Is more ever too much? The number of indicators per factor in confirmatory factor analysis. Multivariate Behavioral Research, 33, 181–220. doi:10.1207/ s15327906mbr3302_1
dc.relation.references99. Hagell P, Westergren A. Sample Size and Statistical Conclusions from Tests of Fit to the Rasch Model According to the Rasch Unidimensional Measurement Model (Rumm) Program in Health Outcome Measurement. J Appl Meas. 2016;17(4):416- 431. PMID: 28009589
dc.relation.references100. Clinically Meaningful Gaps Lai J.-S., Eton D.T. Rasch Measurement Transactions, 2002, 15:4 p. 850. Disponible en: https:// www.rasch.org/rmt/rmt154e.htm
dc.relation.references101. Glorfeld, L. W. (1995). An improvement on Horn's Parallel Analysis Methodology for selecting the correct number of factors to retain. Educational and Psychological Measurement, 55(3), 377-393
dc.relation.references102. DiStefano C, Morgan GB. A comparison of diagonal weighted least squares robust estimation techniques for ordinal data. Struct Equ Modeling. 2014;21(3):425-38. Disponible en: http://dx.doi.org/10.1080/10705511.2014.915373
dc.relation.references103. Li C-H. Confirmatory factor analysis with ordinal data: Comparing robust maximum likelihood and diagonally weighted least squares. Behav Res Methods. 2016;48(3):936-49. Disponible en: http://dx.doi.org/10.3758/s13428-015-0619-7
dc.relation.references104. Mîndrilă D. Maximum likelihood (ML) and diagonally weighted least squares (DWLS) estimation procedures: A comparison of estimation bias with ordinal and multivariate non-normal data. Int J Digit Soc. 2010;1(1):60-6. Disponible en: http://dx.doi.org/10.20533/ijds.2040.2570.2010.0010
dc.relation.references105. Rosseel Y. lavaan: An R Package for Structural Equation Modeling. Journal of Statistical Software. 2012;48(2):1-36
dc.relation.referencesRevelle W. _psych: Procedures for Psychological, Psychometric, and Personality Research_. Northwestern University, Evanston, Illinois. R package version 2.4.3. 2024. Disponible en: https://CRAN.R-project.org/package=psych
dc.relation.references107. Marsh HW, Hau KT, Balla JR, Grayson D. Is more ever too much? The number of indicators per factor in confirmatory factor analysis. Multivariate Behav Res. 1998;33(2):181-220. Disponible en: http://dx.doi.org/10.1207/s15327906mbr3302_1
dc.relation.references108. Koran J. Indicators per Factor in Confirmatory Factor Analysis: More is not Always Better. Struct Equ Modeling. 2020;27(5):765-72. Disponible en: http://dx.doi.org/10.1080/10705511.2019.1706527
dc.relation.references109. Kenny DA. Correlation and Causality. Nashville, TN, Estados Unidos de América: John Wiley & Sons; 1979
dc.relation.referencesHarman HH, Fukuda Y. Resolution of the Heywood case in the minres solution. Psychometrika. 1966;31(4):563-71. Disponible en: http://dx.doi.org/10.1007/bf02289525
dc.relation.references111. What do Infit and Outfit, Mean-square and Standardized mean? Linacre JM. … Rasch Measurement Transactions, 2002, 16:2 p.878
dc.relation.references112. De Jong RW, Stel VS, Heaf JG, Murphy M, Massy ZA, Jager KJ. Non-medical barriers reported by nephrologists when providing renal replacement therapy or comprehensive conservative management to end-stage kidney disease patients: a systematic review. Nephrol Dial Transplant [Internet]. 2021;36(5):848-62. Disponible en: http://dx.doi.org/10.1093/ndt/gfz271
dc.relation.references113. Thiele S, Goebel S, Kröger N, Pedersen A. Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation. Psychooncology. 2020;29(8):1248-54. Disponible en: http://dx.doi.org/10.1002/pon.5397
dc.relation.references114. He J-L, Xu H-Q, Yang J, Hou D-J, Gong X-Y, Lu X-Y, et al. Fear of disease progression among breast cancer patients in China: a meta-analysis of studies using the fear of progression questionnaire short form. Front Psychol. 2023;14:1222798. Disponible en: http://dx.doi.org/10.3389/fpsyg.2023.1222798
dc.relation.references115. Seery C, Buchanan S. The psychosocial needs of patients who have chronic kidney disease without kidney replacement therapy: a thematic synthesis of seven qualitative studies. J Nephrol [Internet]. 2022;35(9):2251-67. Disponible en: http://dx.doi.org/10.1007/s40620- 022-01437-3
dc.relation.references116. Tinte JP. DSM-5 Fácil: Guía esencial de trastornos mentales según el DSM-5: Definiciones y síntomas de más de 130 condiciones psiquiátricas. Independently Published; 2023
dc.relation.references117. Zhang M, Nie S, Hai Z, Du Y, Jiang M, Cai C. Effects of illness perception and coping style on self-management in peritoneal dialysis patients: A cross-sectional study. Psychol Res Behav Manag [Internet]. 2024;17:3381-93. Disponible en: http://dx.doi.org/10.2147/PRBM.S474427
dc.relation.references118. Todd J, Pickup B, Coutts-Bain D. Fear of progression, imagery, interpretation bias, and their relationship with endometriosis pain. Pain [Internet]. 2023;164(12):2839-44. Disponible en: http://dx.doi.org/10.1097/j.pain.0000000000003003
dc.relation.references119. Zheng M, Wang S, Zhu Y, Wan H. Trajectories of fear of progression in nasopharyngeal carcinoma patients receiving proton and heavy ion therapy. Support Care Cancer [Internet]. 2023;31(12):630. Disponible en: http://dx.doi.org/10.1007/s00520-023-08085-8
dc.relation.references120. Farhane-Medina NZ, Luque B, Tabernero C, Castillo-Mayén R. Factors associated with gender and sex differences in anxiety prevalence and comorbidity: A systematic review. Sci Prog [Internet]. 2022;105(4):368504221135469. Disponible en: http://dx.doi.org/10.1177/00368504221135469
dc.relation.references121. Zhang Y, Liu S, Miao Q, Zhang X, Wei H, Feng S, et al. The heterogeneity of symptom burden and fear of progression among kidney transplant recipients: A latent class analysis. Psychol Res Behav Manag [Internet]. 2024;17:1205-19. Disponible en: http://dx.doi.org/10.2147/PRBM.S454787
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.lembENFERMEDADES RENALESspa
dc.subject.lembKidneys - diseaseseng
dc.subject.lembINSUFICIENCIA RENALspa
dc.subject.lembRenal insufficiencyeng
dc.subject.lembCALIDAD DE VIDAspa
dc.subject.lembQuality of lifeeng
dc.subject.lembINDICADORES DE SALUDspa
dc.subject.lembHealth status indicatorseng
dc.subject.lembENCUESTAS DE SALUDspa
dc.subject.lembHealth surveyseng
dc.subject.proposalTemor a la progresiónspa
dc.subject.proposalEnfermedad renalspa
dc.subject.proposalValidaciónspa
dc.subject.proposalSalud mentalspa
dc.subject.proposalFear of progressioneng
dc.subject.proposalKidney diseaseeng
dc.subject.proposalValidationeng
dc.subject.proposalMental healtheng
dc.titleValidación del cuestionario FoP-Q-SF (Fear of Progression Questionnaire- Short Form) para su utilización en la evaluación del temor a la progresión de la enfermedad en pacientes colombianos con enfermedad renal crónicaspa
dc.title.translatedValidation of the FoP-Q-SF (Fear of Progression Questionnaire–Short Form) for use in assessing fear of disease progression in colombian patients with chronic kidney diseaseeng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
2Tesis_Giancarlo_Patiño_2025.pdf
Tamaño:
2.48 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Epidemiología Clínica

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción: